Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pfister

Showing results (101-110 of 194) with videos related to

Pageof 20
Sort By:
Der Urologe. Ausg. A|January 11, 2021
[Using preorchiectomy tumor marker serum concentrations for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging]Pia Paffenholz, Tim Nestler, Yasmine Maatoug, et al.
Therapeutic Advances in Urology|October 2, 2013
Controversies on individualized prostate cancer care: gaps in current practiceSteven Joniau, David Pfister, Alexandre de la Taille, et al.
European Urology Focus|June 25, 2020
Impact of the COVID-19 Pandemic on Urologists in GermanyPia Paffenholz, Arne Peine, Nicolas Fischer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2012
Urinary morbidity after permanent prostate brachytherapy - impact of dose to the urethra vs. sources placed in close vicinity to the urethraMichael Pinkawa, Richard Holy, Marc D Piroth, et al.
BJU International|June 13, 2020
<sup>68</sup> Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancerDavid Pfister, Friederike Haidl, Tim Nestler, et al.
The Journal of Urology|December 12, 2023
Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node DissectionTim Nestler, Pia Paffenholz, David Pfister, et al.
European Urology Oncology|October 16, 2024
Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39Constantin Rieger, Jörg Schlüchtermann, Michaela Lehmann, et al.
The Journal of Urology|February 8, 2024
Reply by AuthorsTim Nestler, Pia Paffenholz, David Pfister, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2009
Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapyLawrence Koutcher, Nancy Lee, Michael Zelefsky, et al.
Nuklearmedizin. Nuclear Medicine|December 17, 2021
Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancerCharlotte A Schneider, Philipp Täger, Jochen Hammes, et al.
Pageof 20

Showing results (101-110 of 194) with videos related to

Sort By:
Pageof 20
Der Urologe. Ausg. A|January 11, 2021
[Using preorchiectomy tumor marker serum concentrations for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging]Pia Paffenholz, Tim Nestler, Yasmine Maatoug, et al.
Therapeutic Advances in Urology|October 2, 2013
Controversies on individualized prostate cancer care: gaps in current practiceSteven Joniau, David Pfister, Alexandre de la Taille, et al.
European Urology Focus|June 25, 2020
Impact of the COVID-19 Pandemic on Urologists in GermanyPia Paffenholz, Arne Peine, Nicolas Fischer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2012
Urinary morbidity after permanent prostate brachytherapy - impact of dose to the urethra vs. sources placed in close vicinity to the urethraMichael Pinkawa, Richard Holy, Marc D Piroth, et al.
BJU International|June 13, 2020
<sup>68</sup> Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancerDavid Pfister, Friederike Haidl, Tim Nestler, et al.
The Journal of Urology|December 12, 2023
Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node DissectionTim Nestler, Pia Paffenholz, David Pfister, et al.
European Urology Oncology|October 16, 2024
Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39Constantin Rieger, Jörg Schlüchtermann, Michaela Lehmann, et al.
The Journal of Urology|February 8, 2024
Reply by AuthorsTim Nestler, Pia Paffenholz, David Pfister, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2009
Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapyLawrence Koutcher, Nancy Lee, Michael Zelefsky, et al.
Nuklearmedizin. Nuclear Medicine|December 17, 2021
Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancerCharlotte A Schneider, Philipp Täger, Jochen Hammes, et al.
Pageof 20